The expression of CXCR2 ligands, CXCL1-3 and CXCL5-8 by melanoma cells has been shown to control the immune cell composition of the TME, to contribute to the ability to escape tumor immune surveillance, to induce angiogenesis or to define the preferred sites of melanoma metastases86–89. This evidence concerns the gene CXCR2 and neoplasm.